BR9609467A - Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária - Google Patents

Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária

Info

Publication number
BR9609467A
BR9609467A BR9609467A BR9609467A BR9609467A BR 9609467 A BR9609467 A BR 9609467A BR 9609467 A BR9609467 A BR 9609467A BR 9609467 A BR9609467 A BR 9609467A BR 9609467 A BR9609467 A BR 9609467A
Authority
BR
Brazil
Prior art keywords
compound
plank
treating
preparing
processes
Prior art date
Application number
BR9609467A
Other languages
English (en)
Portuguese (pt)
Inventor
David Cox
Anthony Ingall
Paul Willis
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en
Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en
Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of BR9609467A publication Critical patent/BR9609467A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR9609467A 1995-07-11 1996-07-04 Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária BR9609467A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9514074.5A GB9514074D0 (en) 1995-07-11 1995-07-11 Compounds
GBGB9520311.3A GB9520311D0 (en) 1995-10-05 1995-10-05 Compounds
GBGB9522837.5A GB9522837D0 (en) 1995-11-08 1995-11-08 Compounds
PCT/SE1996/000911 WO1997003084A1 (en) 1995-07-11 1996-07-04 New inhibitors of platelet aggregation

Publications (1)

Publication Number Publication Date
BR9609467A true BR9609467A (pt) 1999-03-02

Family

ID=27267806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609467A BR9609467A (pt) 1995-07-11 1996-07-04 Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária

Country Status (25)

Country Link
US (1) US5747496A (enExample)
EP (1) EP0840740B1 (enExample)
JP (1) JP4084415B2 (enExample)
KR (1) KR100444123B1 (enExample)
CN (1) CN1069321C (enExample)
AR (1) AR003453A1 (enExample)
AT (1) ATE217010T1 (enExample)
AU (1) AU699034B2 (enExample)
BR (1) BR9609467A (enExample)
CA (1) CA2226758A1 (enExample)
CZ (1) CZ297200B6 (enExample)
DE (1) DE69621021T2 (enExample)
EE (1) EE03616B1 (enExample)
HU (1) HU221880B1 (enExample)
IL (1) IL122814A (enExample)
IS (1) IS1790B (enExample)
MY (1) MY116542A (enExample)
NO (1) NO310624B1 (enExample)
NZ (1) NZ312258A (enExample)
PL (1) PL182680B1 (enExample)
SA (1) SA96170272B1 (enExample)
SK (1) SK283206B6 (enExample)
TR (1) TR199800019T1 (enExample)
TW (1) TW427996B (enExample)
WO (1) WO1997003084A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4125790B2 (ja) * 1996-12-20 2008-07-30 アストラゼネカ・アクチエボラーグ トリアゾロ［４，５−ｄ］ピリミジニル誘導体および医薬としてのその使用
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
DE69905451T2 (de) * 1998-02-17 2003-11-20 Astrazeneca Uk Ltd., London Neue triazolo(4,5d) pyrimidinverbindungen
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
DE602004018637D1 (de) * 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
EP1615930A2 (en) * 2003-04-09 2006-01-18 Biogen Idec MA, Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
WO2004092177A1 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
GB2422782A (en) * 2003-10-21 2006-08-09 Inspire Pharmaceuticals Inc Non-nucleotide compositions and method for treating pain
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
EP1685135B1 (en) * 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. TETRAHYDRO-FURO[3,4-d]DIOXOLE COMPOUNDS AND COMPOSITIONS AND METHOD FOR INHIBITING PLATELET AGGREGATION
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7932376B2 (en) * 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
WO2008054795A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
JP5654990B2 (ja) * 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
US8859769B2 (en) 2010-02-16 2014-10-14 Actavis Group Ptc Ehf Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
BR112014013085A2 (pt) 2011-11-30 2017-06-13 Actavis Group Ptc Ehf forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
WO2014206188A1 (zh) * 2013-06-27 2014-12-31 苏州明锐医药科技有限公司 替格瑞洛的制备方法
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN112915063B (zh) * 2021-01-25 2022-12-20 刘红枚 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) * 2021-07-05 2022-04-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
US5506347A (en) * 1993-02-03 1996-04-09 Gensia, Inc. Lyxofuranosyl analogues of adenosine
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain

Also Published As

Publication number Publication date
IS4647A (is) 1998-01-08
NO310624B1 (no) 2001-07-30
HUP9802448A2 (hu) 1999-05-28
DE69621021T2 (de) 2002-10-31
IL122814A0 (en) 1998-08-16
CZ297200B6 (cs) 2006-09-13
EP0840740B1 (en) 2002-05-02
KR19990028885A (ko) 1999-04-15
AU6375196A (en) 1997-02-10
US5747496A (en) 1998-05-05
WO1997003084A1 (en) 1997-01-30
EP0840740A1 (en) 1998-05-13
AU699034B2 (en) 1998-11-19
EE03616B1 (et) 2002-02-15
KR100444123B1 (ko) 2004-10-14
HU221880B1 (hu) 2003-02-28
CZ2598A3 (cs) 1998-08-12
MY116542A (en) 2004-02-28
NO980080D0 (no) 1998-01-08
EE9800026A (et) 1998-08-17
MX9800308A (es) 1998-09-30
CN1069321C (zh) 2001-08-08
TR199800019T1 (xx) 1998-05-21
HUP9802448A3 (en) 2000-03-28
DE69621021D1 (de) 2002-06-06
SK2398A3 (en) 1999-01-11
AR003453A1 (es) 1998-08-05
SK283206B6 (sk) 2003-03-04
PL324396A1 (en) 1998-05-25
PL182680B1 (pl) 2002-02-28
NZ312258A (en) 1999-08-30
CN1195353A (zh) 1998-10-07
ATE217010T1 (de) 2002-05-15
SA96170272B1 (ar) 2006-06-04
CA2226758A1 (en) 1997-01-30
JP4084415B2 (ja) 2008-04-30
TW427996B (en) 2001-04-01
IS1790B (is) 2001-11-28
NO980080L (no) 1998-03-06
IL122814A (en) 2001-04-30
JPH11508914A (ja) 1999-08-03

Similar Documents

Publication Publication Date Title
BR9609467A (pt) Composto uso de um composto composição farmacéutica e processos para preparação de um composto e tratamento de distúrbios de agregação planquetária
BR9602705A (pt) Composto composição farmacéutica processo para a preparação de um composto e uso
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9501770A (pt) Uso de um composto,composto,formulação farmacêutica e processo para preparar um composto
BR1100323A (pt) Composto, uso de um composto, composição farmacêutica e processo para preparar um composto
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
BR9406128A (pt) Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
BR9610248A (pt) Composto composição farmacêutica processos para o tratamento da dor e para a preparação de um composto e uso do composto
BR9100435A (pt) Composto,composicao farmaceutica,uso,metodo de tratamento de um animal,processos para a preparacao da um composto e de uma composicao farmaceutica
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9600930A (pt) Derivados de n-(3-benzofuranil)uréia processo para sua preparação composição processo para a preparação de composições e uso
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR9610988A (pt) Composto uso do mesmo fomulação farmacêutica e processo para produção do composto
BR9505610A (pt) Composto composição farmacéutica processo para a preparação de um composto uso e método de tratar inflamação e dor
BR9602150A (pt) Compostos processo para sua preparação processo para a produção de uma formulação farmacêutica formulação farmacêutica e uso
BR9711311A (pt) Composto composi-Æo farmac-utica uso de um composto e processos para a prepara-Æo de compostos e para tratamento de um mamifero incluindo o homem
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR9708093A (pt) Composto formulação uso composto e processo para tratamento de distúrbios mediados por 5-hidroxitriptamina e para preparação do composto
BR9609327A (pt) Novos derivados de oxazolidinona processos para sua preparação e agentes farmacêuticos que contêm estes compostos
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9607095A (pt) Composto composição farmacêutica e processos para fabricar e para administrar um composto

Legal Events

Date Code Title Description
PC Transfer

Free format text: ASTRAZENECA AB (SE)

FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time